Mahboobeh Safaeian

Summary

Publications

  1. ncbi Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
    Obstet Gynecol 109:1325-31. 2007
  2. pmc Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    J Natl Cancer Inst 102:1794-804. 2010
  3. pmc Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 7:e33619. 2012
  4. pmc Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure
    Sarah E Coseo
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    Sex Transm Dis 38:976-82. 2011
  5. pmc Determinants of seropositivity among HPV-16/18 DNA positive young women
    Carolina Porras
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    BMC Infect Dis 10:238. 2010
  6. pmc Determinants and correlation of systemic and cervical concentrations of total IgA and IgG
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, 6120 Executive Boulevard, Suite 550, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 18:2672-6. 2009
  7. pmc HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays
    Shih Wen Lin
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 8:e53067. 2013
  8. pmc Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Ste 550, Rockville, MD 20852, USA
    J Natl Cancer Inst 102:1653-62. 2010
  9. doi Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica
    Sarah Coseo
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS, Room 7079, Rockville, MD 20852, USA
    Sex Transm Dis 37:706-14. 2010
  10. pmc A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia
    Mark Schiffman
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    Cancer Res 70:3159-69. 2010

Collaborators

Detail Information

Publications23

  1. ncbi Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics and Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20852, USA
    Obstet Gynecol 109:1325-31. 2007
    ....
  2. pmc Chlamydia trachomatis and risk of prevalent and incident cervical premalignancy in a population-based cohort
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    J Natl Cancer Inst 102:1794-804. 2010
    ..In a large prospective cohort, we assessed the role of C trachomatis in cervical premalignancy and addressed confounding by HPV...
  3. pmc Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of HPV persistence and cervical precancer/cancer
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 7:e33619. 2012
    ..Host genetic factors might affect the risk of progression from infection with carcinogenic human papillomavirus (HPV), the etiologic agent for cervical cancer, to persistent HPV infection, and hence to cervical precancer and cancer...
  4. pmc Evaluation of the polyclonal ELISA HPV serology assay as a biomarker for human papillomavirus exposure
    Sarah E Coseo
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD 20852, USA
    Sex Transm Dis 38:976-82. 2011
    ..Overall performance of these assays, as a measure of HPV exposure, has not been evaluated...
  5. pmc Determinants of seropositivity among HPV-16/18 DNA positive young women
    Carolina Porras
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA
    BMC Infect Dis 10:238. 2010
    ..We evaluated determinants of seropositivity among 646 women infected with HPV-16 and/or HPV-18...
  6. pmc Determinants and correlation of systemic and cervical concentrations of total IgA and IgG
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, 6120 Executive Boulevard, Suite 550, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 18:2672-6. 2009
    ..17 and 0.16, respectively). The lack of correlation between systemic and cervical total IgA and IgG suggests that systemic concentrations are not reflective of cervical levels...
  7. pmc HPV16 seropositivity and subsequent HPV16 infection risk in a naturally infected population: comparison of serological assays
    Shih Wen Lin
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, Maryland, United States of America
    PLoS ONE 8:e53067. 2013
    ....
  8. pmc Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, National Institutes of Health, 6120 Executive Blvd, Ste 550, Rockville, MD 20852, USA
    J Natl Cancer Inst 102:1653-62. 2010
    ..Infection with human papillomavirus (HPV) 16 or HPV18 elicits an antibody response, but whether the elicited antibodies protect women against subsequent infection by a homologous HPV type compared with seronegative women is unknown...
  9. doi Seroprevalence and correlates of human papillomavirus 16/18 seropositivity among young women in Costa Rica
    Sarah Coseo
    Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, DHHS, 6120 Executive Blvd, EPS, Room 7079, Rockville, MD 20852, USA
    Sex Transm Dis 37:706-14. 2010
    ..We investigated HPV16 and 18 seroepidemiology among young, unvaccinated women aged between 18 and 25...
  10. pmc A population-based prospective study of carcinogenic human papillomavirus variant lineages, viral persistence, and cervical neoplasia
    Mark Schiffman
    Divisions of Cancer Epidemiology and Genetics and Cancer Prevention, National Cancer Institute, Bethesda, Maryland 20852, USA
    Cancer Res 70:3159-69. 2010
    ..Larger viral genomic studies are warranted, especially to identify the genetic basis for HPV16's unique carcinogenicity...
  11. pmc Prevalence of and risk factors for oral human papillomavirus among young women in Costa Rica
    Krystle A Lang Kuhs
    National Cancer Institute, National Institutes of Health, Bethesda, Maryland
    J Infect Dis 208:1643-52. 2013
    ..Little is known about the epidemiology of oral human papillomavirus (HPV) in Latin America...
  12. ncbi Direct comparison of HPV16 serological assays used to define HPV-naïve women in HPV vaccine trials
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Epidemiol Biomarkers Prev 21:1547-54. 2012
    ..Some of the variation in estimated vaccine efficacies may be due to the differences in these assays used to define the HPV-naïve subgroups. To guide the interpretation of published results, we compared these assays...
  13. pmc Human papillomavirus cofactors by disease progression and human papillomavirus types in the study to understand cervical cancer early endpoints and determinants
    Sophia S Wang
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Room 5104, Rockville, MD 20854 7234, USA
    Cancer Epidemiol Biomarkers Prev 18:113-20. 2009
    ..Investigations on the molecular distinctions along the disease continuum of cervical pathogenesis by HPV type are needed...
  14. ncbi Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Infections and Immunoepidemiology Branch, National Cancer Institute, 9609 Medical Center Drive, Rm 6 E224, MSC 9767, Bethesda, MD 20892
    Cancer Prev Res (Phila) 6:1242-50. 2013
    ..Antibody levels following one-dose remained stable from month 6 through month 48. Results raise the possibility that even a single dose of HPV VLPs will induce long-term protection...
  15. pmc A competitive serological assay shows naturally acquired immunity to human papillomavirus infections in the Guanacaste Natural History Study
    Nicolas Wentzensen
    National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 204:94-102. 2011
    ..A competitive Luminex Immunoassay (cLIA) has been developed to measure neutralizing antibodies against human papillomavirus (HPV) types 6, 11, 16 and 18...
  16. pmc Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus
    Hilary A Robbins
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, Maryland, USA
    BMC Infect Dis 14:120. 2014
    ..We evaluated the high-throughput GST-L1, which is increasingly used in epidemiologic research, as a measure of cumulative HPV infection and future immune protection among HPV-unvaccinated women...
  17. pmc Lack of heterogeneity of HPV16 E7 sequence compared with HPV31 and HPV73 may be related to its unique carcinogenic properties
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
    Arch Virol 155:367-70. 2010
    ..The lack of heterogeneity of HPV16 E7 suggests high evolutionary purifying selection that might be related to the unique carcinogenicity of HPV16...
  18. pmc Detection of precancerous cervical lesions is differential by human papillomavirus type
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Cancer Res 69:3262-6. 2009
    ..001). These results indicate the underrepresentation of HPV18/45 in precancers, whereas HPV16-associated CIN3+ is diagnosed much earlier. Whether the underrepresentation of 18/45 may be due to occult pathology needs further investigation...
  19. ncbi Comparability of self-collected vaginal swabs and physician-collected cervical swabs for detection of human papillomavirus infections in Rakai, Uganda
    Mahboobeh Safaeian
    Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland 20852, USA
    Sex Transm Dis 34:429-36. 2007
    ..The objective of this study was to compare human papillomavirus (HPV) DNA testing between self-administered vaginal swabs and physician-administered cervical swabs in women from rural Rakai District, Uganda...
  20. doi Factors associated with fluctuations in IgA and IgG levels at the cervix during the menstrual cycle
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Infect Dis 199:455-63. 2009
    ..The objective of this analysis was to describe patterns and determinants of cervical immunoglobulin A (IgA) and G (IgG) levels during the menstrual cycle...
  21. pmc Cervical cancer prevention--cervical screening: science in evolution
    Mahboobeh Safaeian
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health DHHS, 6120 Executive Blvd, Rockville, MD 20852, USA
    Obstet Gynecol Clin North Am 34:739-60, ix. 2007
    ..This article describes the traditional methods of screening for cervical cancer and innovative methods that might help overcome financial and cultural barriers to more widespread screening...
  22. doi Medical history and the risk of biliary tract cancers in Shanghai, China: implications for a role of inflammation
    Gabriella Andreotti
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd, EPS 8011, MSC 7240, Bethesda, MD 20892, USA
    Cancer Causes Control 22:1289-96. 2011
    ..2-15.0) or duodenal ulcers (OR = 3.7, 1.2-12.0) was associated with an excess risk of gallbladder cancer. Although the mechanisms are unclear, our results further support the role for inflammation in the etiology of biliary tract cancers...
  23. pmc Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica
    Mahboobeh Safaeian
    Division of Cancer Epidemiology and Genetics, Hormonal and Reproductive Epidemiology Branch, National Cancer Institute, 6120 Executive Boulevard, Suite 550, Rockville, MD 20852, USA
    J Clin Microbiol 45:1447-54. 2007
    ..The crude agreement between the two assays was 88%, with a kappa value of 0.75 (95% confidence limits, 0.73 to 0.76). We observed very good agreement between HC2 and SPF(10)-LiPA for carcinogenic HPV type detection...